Predictive Oncology Raises $344M for Digital Asset Treasury Strategy Centered on Aethir Tokens, Shares Up 72%
Predictive Oncology Inc. (NASDAQ: POAI) announced it has priced two private placement transactions totaling approximately $344 million to support its newly launched digital asset treasury strategy. The initiative will center on acquiring and holding Aethir (ATH) tokens, the native utility token of the Aethir decentralized GPU network.
Transaction Details
The financing includes two components:
Cash PIPE: $51.7 million in gross proceeds through the sale of approximately 66.7 million shares of common stock (or equivalent pre-funded warrants) at $0.7751 per share.
Crypto PIPE: $292.7 million in pre-funded warrants tied to in-kind contributions of locked and unlocked Aethir tokens, representing $173.3 million in discounted value.
Both transactions are expected to close on or about October 2, 2025, subject to customary conditions. The company will also seek shareholder approval for the exercise of pre-funded warrants issued in the Crypto PIPE.
Net proceeds will be used to expand Predictive Oncology’s ATH holdings through open-market purchases, in addition to general corporate purposes and working capital.
Strategic Shift Toward AI Infrastructure
Aethir operates a global decentralized GPU network spanning more than 435,000 GPU containers across 200+ locations in 93 countries, offering Nvidia GPUs-as-a-Service at an estimated 40–80% cost savings compared to traditional providers. By integrating ATH tokens into its treasury, Predictive Oncology aims to establish what it calls the world’s first “Strategic Compute Reserve,” positioning itself as both an investor and operator within the Aethir ecosystem.
The company highlighted a unique incentive: for each ATH token purchased on the open market, it will receive an additional 20% token allocation from the DCI Foundation, further aligning token demand with GPU infrastructure growth.
Leadership and Governance
As part of the deal, Shawn Matthews—CEO of DNA Holdings Venture and former CEO of Cantor Fitzgerald—will join Predictive Oncology’s board upon closing. DNA Holdings will also serve as strategic advisor for the company’s digital asset treasury initiative.
H.C. Wainwright & Co. acted as the exclusive placement agent for the PIPEs, with legal counsel from DLA Piper LLP (US) for the company and Sheppard, Mullin, Richter & Hampton LLP for DNA Holdings.
Management Commentary
Raymond Vennare, CEO and Chairman of Predictive Oncology, said the strategy expands both the company’s oncology-focused AI drug discovery platform and its exposure to digital assets:
“Our partnership with Aethir represents a seminal event for Predictive Oncology and we believe it creates an outstanding opportunity to solidify and expand our core business while embarking upon incremental growth through our digital asset treasury strategy.”
Aethir’s Co-Founder and CEO, Dan Wang, added that Predictive Oncology’s role will extend beyond treasury management:
“With planned holdings of ATH, the company will be able to function as an operator on the Aethir ecosystem, strengthening its ability to provide the global infrastructure layer for the future of AI.”
Investor Takeaways
For shareholders, the $344 million financing marks a significant pivot, giving Predictive Oncology exposure to blockchain-based GPU infrastructure while maintaining its focus on AI-driven oncology drug discovery. Success of this dual strategy will depend on the integration of ATH into the company’s treasury, execution of the “Strategic Compute Reserve,” and eventual monetization of digital assets alongside its drug development platform.
